Screening Sarcoidosis Patients for Occult Disease

Abstract

As sarcoidosis may involve any organ, sarcoidosis patients should be evaluated for occult disease. Screening for some organ involvement may not be warranted if it is unlikely to cause symptoms, organ dysfunction, or affect clinical outcome. Even organ involvement that affects clinical outcome does not necessarily require screening if early detection fails to change the patient's quality of life or prognosis. On the other hand, early detection of some forms of sarcoidosis may improve outcomes and survival. This manuscript describes the approach to screening sarcoidosis patients for previously undetected disease. Screening for sarcoidosis should commence with a meticulous medical history and physical examination. Many sarcoidosis patients present with physical signs or symptoms of sarcoidosis that have not been recognized as manifestations of the disease. Detection of sarcoidosis in these instances depends on the clinician's familiarity with the varied clinical presentations of sarcoidosis. In addition, sarcoidosis patients may present with symptoms or signs that are not related to specific organ involvement that have been described as parasarcoidosis syndromes. It is conjectured that parasarcoidosis syndromes result from systemic release of inflammatory mediators from the sarcoidosis granuloma. Certain forms of sarcoidosis may cause permanent and serious problems that can be prevented if they are detected early in the course of their disease. These include (1) ocular involvement that may lead to permanent vision impairment; (2) vitamin D dysregulation that may lead to hypercalcemia, nephrolithiasis, and permanent kidney injury; and (3) cardiac sarcoidosis that may lead to a cardiomyopathy, ventricular arrhythmias, heart block, and sudden death. Screening for these forms of organ involvement requires detailed screening approaches.

Keywords

sarcoidosis - screening - symptoms - cardiac - vitamin D

Publikationsverlauf

Artikel online veröffentlicht:
10. August 2020

• References

• 1 Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132 (06) 1949-1953
• 2 Tavora F, Cresswell N, Li L, Ripple M, Solomon C, Burke A. Comparison of necropsy findings in patients with sarcoidosis dying suddenly from cardiac sarcoidosis versus dying suddenly from other causes. Am J Cardiol 2009; 104 (04) 571-577
• 3 Judson MA. The clinical features of sarcoidosis: a comprehensive review. Clin Rev Allergy Immunol 2015; 49 (01) 63-78
• 4 Herman C. What makes a screening exam “good”?. Virtual Mentor 2006; 8 (01) 34-37
• 5 Bell NR, Grad R, Dickinson JA, et al. Better decision making in preventive health screening: balancing benefits and harms. Can Fam Physician 2017;63(07):521–524
• 6 Hunninghake GW, Costabel U, Ando M. , et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16 (02) 149-173
• 7 Moller DR. Negative clinical trials in sarcoidosis: failed therapies or flawed study design?. Eur Respir J 2014; 44 (05) 1123-1126
• 8 Nakatsu M, Hatabu H, Morikawa K. , et al. Large coalescent parenchymal nodules in pulmonary sarcoidosis: “sarcoid galaxy” sign. AJR Am J Roentgenol 2002; 178 (06) 1389-1393
• 9 Ohara K, Judson MA, Baughman RP. Clinical aspects of ocular sarcoidosis. Eur Respir J Monograph 2005; 10: 188-209
• 10 Eklund A, Rizzato G. Skin manifestations in sarcoidosis. Eur Respir J Monograph 2005; 10: 150-163
• 11 Mañá J, Gómez-Vaquero C, Montero A. , et al. Löfgren's syndrome revisited: a study of 186 patients. Am J Med 1999; 107 (03) 240-245
• 12 Okamoto H, Mizuno K, Imamura S, Nagai S, Izumi T. Erythema nodosum-like eruption in sarcoidosis. Clin Exp Dermatol 1994; 19 (06) 507-510
• 13 Marchell RM, Judson MA. Cutaneous sarcoidosis. Semin Respir Crit Care Med 2010; 31 (04) 442-451
• 14 Antonovich DD, Callen JP. Development of sarcoidosis in cosmetic tattoos. Arch Dermatol 2005; 141 (07) 869-872
• 15 Chao SC, Yan JJ, Lee JY. Cutaneous sarcoidosis among Taiwanese. J Formos Med Assoc 2000; 99 (04) 317-323
• 16 McKinzie BP, Bullington WM, Mazur JE, Judson MA. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci 2010; 339 (01) 1-4
• 17 Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial biopsy for sarcoidosis: a prospective study. Chest 2001; 120 (01) 109-114
• 18 Kalkanis A, Judson MA. Distinguishing asthma from sarcoidosis: an approach to a problem that is not always solvable. J Asthma 2013; 50 (01) 1-6
• 19 Baughman RP, Shipley RT, Loudon RG, Lower EE. Crackles in interstitial lung disease. Comparison of sarcoidosis and fibrosing alveolitis. Chest 1991; 100 (01) 96-101
• 20 Tavee J, Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep 2011; 15 (03) 201-206
• 21 Drent M, Wirnsberger RM, de Vries J, van Dieijen-Visser MP, Wouters EF, Schols AM. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J 1999; 13 (04) 718-722
• 22 Bakkers M, Merkies IS, Lauria G. , et al. Intraepidermal nerve fiber density and its application in sarcoidosis. Neurology 2009; 73 (14) 1142-1148
• 23 Hoitsma E, Marziniak M, Faber CG. , et al. Small fibre neuropathy in sarcoidosis. Lancet 2002; 359 (9323): 2085-2086
• 24 Parambil JG, Tavee JO, Zhou L, Pearson KS, Culver DA. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respir Med 2011; 105 (01) 101-105
• 25 Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med 2017; 126: 135-138
• 26 Devigili G, Tugnoli V, Penza P. , et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 2008; 131 (Pt 7): 1912-1925
• 27 Reulen JP, Lansbergen MD, Verstraete E, Spaans F. Comparison of thermal threshold tests to assess small nerve fiber function: limits vs. levels. Clin Neurophysiol 2003; 114 (03) 556-563
• 28 Truini A, Galeotti F, Romaniello A, Virtuoso M, Iannetti GD, Cruccu G. Laser-evoked potentials: normative values. Clin Neurophysiol 2005; 116 (04) 821-826
• 29 Low PA, Caskey PE, Tuck RR, Fealey RD, Dyck PJ. Quantitative sudomotor axon reflex test in normal and neuropathic subjects. Ann Neurol 1983; 14 (05) 573-580
• 30 Brines M, Culver DA, Ferdousi M. , et al. Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy. Sci Rep 2018; 8 (01) 4734
• 31 Culver DA, Dahan A, Bajorunas D. , et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci 2017; 58 (06) BIO52-BIO60
• 32 Heij L, Niesters M, Swartjes M. , et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med 2012; 18: 1430-1436
• 33 Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40 (01) 255-263
• 34 Lower EE, Weiss KL. Neurosarcoidosis. Clin Chest Med 2008; 29 (03) 475-492 , ix
• 35 Agarwal R, Aggarwal AN, Dhooria S. , et al. A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J 2016; 47 (02) 490-498
• 36 Wagner MT, Marion SD, Judson MA. The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 (03) 235
• 37 Lower EE, Malhotra A, Surdulescu V, Baughman RP. Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage 2013; 45 (02) 159-169
• 38 Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest 2008; 133 (05) 1189-1195
• 39 Strookappe B, Elfferich M, Swigris J. , et al. Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: a pilot study. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32 (01) 43-52
• 40 Strookappe B, Swigris J, De Vries J, Elfferich M, Knevel T, Drent M. Benefits of physical training in sarcoidosis. Lung 2015; 193 (05) 701-708
• 41 Marcellis R, Van der Veeke M, Mesters I. , et al. Does physical training reduce fatigue in sarcoidosis?. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32 (01) 53-62
• 42 Wijnen PA, Cremers JP, Nelemans PJ. , et al. Association of the TNF-α G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J 2014; 43 (06) 1730-1739
• 43 Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012; 250 (05) 713-720
• 44 Requena L, Yus ES. Panniculitis. Part I. Mostly septal panniculitis. J Am Acad Dermatol 2001; 45 (02) 163-183 , quiz 184–186
• 45 Lofgren S, Lundback H. The bilateral hilar lymphoma syndrome; a study of the relation to age and sex in 212 cases. Acta Med Scand 1952; 142 (04) 259-264
• 46 Karakaya B, Kaiser Y, van Moorsel CHM, Grunewald J. Löfgren's syndrome: diagnosis, management, and disease pathogenesis. Semin Respir Crit Care Med 2017; 38 (04) 463-476
• 47 Torralba KD, Quismorio Jr FP. Sarcoid arthritis: a review of clinical features, pathology and therapy. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20 (02) 95-103
• 48 Gran JT, Bøhmer E. Acute sarcoid arthritis: a favourable outcome? A retrospective survey of 49 patients with review of the literature. Scand J Rheumatol 1996; 25 (02) 70-73
• 49 Judson MA, Elicker BM, Colby TV. , et al. The development of sarcoidosis in patients receiving daclizumab: a case series from multiple clinical trials. Respir Med 2019; 149: 23-27
• 50 Highland KB, Retalis P, Coppage L, Schabel SI, Judson MA. Is there an anatomic explanation for chest pain in patients with pulmonary sarcoidosis?. South Med J 1997; 90 (09) 911-914
• 51 De Vries J, Wirnsberger RM. Fatigue, quality of life and health status in sarcoidosis. Eur Respir J Monograph 2005; 32: 92-104
• 52 Gvozdenovic BS, Mihailovic-Vucinic V, Ilic-Dudvarski A, Zugic V, Judson MA. Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med 2008; 102 (11) 1636-1642
• 53 Judson MA. Quality of life in sarcoidosis. Semin Respir Crit Care Med 2017; 38 (04) 546-558
• 54 Elfferich MD, Nelemans PJ, Ponds RW, De Vries J, Wijnen PA, Drent M. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration 2010; 80 (03) 212-219
• 55 Hu X, Carmona EM, Yi ES, Pellikka PA, Ryu J. Causes of death in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33 (03) 275-280
• 56 Huang CT, Heurich AE, Sutton AL, Lyons HA. Mortality in sarcoidosis. A changing pattern of the causes of death. Eur J Respir Dis 1981; 62 (04) 231-238
• 57 Kouranos V, Tzelepis GE, Rapti A. , et al. Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis. JACC Cardiovasc Imaging 2017; 10 (12) 1437-1447
• 58 Mehta D, Lubitz SA, Frankel Z. , et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008; 133 (06) 1426-1435
• 59 Birnie DH, Sauer WH, Bogun F. , et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11 (07) 1305-1323
• 60 Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest 2012; 141 (01) 154-162
• 61 Hamzeh N, Steckman DA, Sauer WH, Judson MA. Pathophysiology and clinical management of cardiac sarcoidosis. Nat Rev Cardiol 2015; 12 (05) 278-288
• 62 Kim JS, Judson MA, Donnino R. , et al. Cardiac sarcoidosis. Am Heart J 2009; 157 (01) 9-21
• 63 Ardehali H, Howard DL, Hariri A. , et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 2005; 150 (03) 459-463
• 64 Smedema JP, Snoep G, van Kroonenburgh MP. , et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005; 45 (10) 1683-1690
• 65 Yoshida A, Ishibashi-Ueda H, Yamada N. , et al. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. Eur J Heart Fail 2013; 15 (02) 166-175
• 66 Youssef G, Leung E, Mylonas I. , et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012; 53 (02) 241-248
• 67 Hena KM, Yip J, Jaber N. , et al; FDNY Sarcoidosis Clinical Research Group*. Clinical course of sarcoidosis in World Trade Center-exposed firefighters. Chest 2018; 153 (01) 114-123
• 68 Blankstein R, Osborne M, Naya M. , et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014; 63 (04) 329-336
• 69 Coleman GC, Shaw PW, Balfour Jr PC. , et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis. JACC Cardiovasc Imaging 2017; 10 (04) 411-420
• 70 Martusewicz-Boros MM, Boros PW, Wiatr E, Zych J, Piotrowska-Kownacka D, Roszkowski-Śliż K. Prevalence of cardiac sarcoidosis in white population: a case-control study: proposal for a novel risk index based on commonly available tests. Medicine (Baltimore) 2016; 95 (32) e4518
• 71 Padala SK, Peaslee S, Sidhu MS, Steckman DA, Judson MA. Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis. Int J Cardiol 2017; 227: 565-570
• 72 Baughman RP, Teirstein AS, Judson MA. , et al; Case Control Etiologic Study of Sarcoidosis (ACCESS) Research Group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164 (10, Pt 1): 1885-1889
• 73 Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (02) 119-127
• 74 Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol 2000; 84 (01) 110-116
• 75 Bradley D, Baughman RP, Raymond L, Kaufman AH. Ocular manifestations of sarcoidosis. Semin Respir Crit Care Med 2002; 23 (06) 543-548
• 76 Mayers M. Ocular sarcoidosis. Int Ophthalmol Clin 1990; 30 (04) 257-263
• 77 Yanardag H, Pamuk ON. Lacrimal gland involvement in sarcoidosis. The clinical features of 9 patients. Swiss Med Wkly 2003; 133 (27–28): 388-391
• 78 Pefkianaki M, Androudi S, Praidou A. , et al. Ocular disease awareness and pattern of ocular manifestation in patients with biopsy-proven lung sarcoidosis. J Ophthalmic Inflamm Infect 2011; 1 (04) 141-145
• 79 Pasadhika S, Rosenbaum JT. Ocular sarcoidosis. Clin Chest Med 2015; 36 (04) 669-683
• 80 Bell NH, Stern PH, Pantzer E, Sinha TK, DeLuca HF. Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. J Clin Invest 1979; 64 (01) 218-225
• 81 Adams JS, Sharma OP, Gacad MA, Singer FR. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest 1983; 72 (05) 1856-1860
• 82 Adams JS, Gacad MA. Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exp Med 1985; 161 (04) 755-765
• 83 Lavery K, Gilden DJ, Saint S, Judson MA, Dhaliwal G. A bare-bones approach. N Engl J Med 2017; 376 (14) 1371-1376
• 84 Casella FJ, Allon M. The kidney in sarcoidosis. J Am Soc Nephrol 1993; 3 (09) 1555-1562
• 85 Sharma OP. Renal sarcoidosis and hypercalcemia. Eur Respir J Monograph 2005; 32: 220-232
• 86 Berliner AR, Haas M, Choi MJ. Sarcoidosis: the nephrologist's perspective. Am J Kidney Dis 2006; 48 (05) 856-870
• 87 Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin Respir Crit Care Med 2010; 31 (04) 474-484
• 88 Baughman RP, Janovcik J, Ray M, Sweiss N, Lower EE. Calcium and vitamin D metabolism in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30 (02) 113-120
• 89 Vucinic V, Skodric-Trifunovic V, Ignjatović S. How to diagnose and manage difficult problems of calcium metabolism in sarcoidosis: an evidence-based review. Curr Opin Pulm Med 2011; 17 (05) 297-302
• 90 Saha BK, Burns SL, Foulke LA, Judson MA. Rare case of parathyroid gland sarcoidosis presenting with hypercalcaemia. BMJ Case Rep 2019; 12 (07) e230598
• 91 Mahévas M, Lescure FX, Boffa JJ. , et al. Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine (Baltimore) 2009; 88 (02) 98-106
• 92 Judson MA. The three tiers of screening for sarcoidosis organ involvement. Respir Med 2016; 113: 42-49
• 93 James WE, Koutroumpakis E, Saha B. , et al. Clinical features of extrapulmonary sarcoidosis without lung involvement. Chest 2018; 154 (02) 349-356
• 94 Kurata A, Terado Y, Izumi M, Fujioka Y, Franke FE. Where does the antigen of cutaneous sarcoidosis come from?. J Cutan Pathol 2010; 37 (02) 211-221
• 95 Bordignon M, Rottoli P, Agostini C, Alaibac M. Adaptive immune responses in primary cutaneous sarcoidosis. Clin Dev Immunol 2011; 2011: 235142
• 96 Judson MA, Baughman RP. How many organs need to be involved to diagnose sarcoidosis?: an unanswered question that, hopefully, will become irrelevant. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31 (01) 6-7
• 97 Lynch III JP, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clin Chest Med 1997; 18 (04) 755-785
• 98 Nunes H, Uzunhan Y, Gille T, Lamberto C, Valeyre D, Brillet PY. Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function. Eur Respir J 2012; 40 (03) 750-765
• 99 Russo JJ, Nery PB, Ha AC. , et al. Sensitivity and specificity of chest imaging for sarcoidosis screening in patients with cardiac presentations. Sarcoidosis Vasc Diffuse Lung Dis 2019; 36 (01) 18-24
• 100 Kobak S, Saydam G, Ince O, Sever F. SAT0551 sensitivity of chest radiography in the early diagnosis of sarcoidosis: is it really should be done?. Ann Rheum Dis 2015; 74: 853-859
• 101 Naidich D. Are CT findings of pulmonary sarcoidosis ever sufficient for a presumptive diagnosis?. Lancet Respir Med 2018; 6 (09) e43
• 102 Hu-Wang E, Schuzer JL, Rollison S. , et al. Chest CT scan at radiation dose of a posteroanterior and lateral chest radiograph series: a proof of principle in lymphangioleiomyomatosis. Chest 2019; 155 (03) 528-533
• 103 Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357 (22) 2277-2284
• 104 Irani SK, Dobbins III WO. Hepatic granulomas: review of 73 patients from one hospital and survey of the literature. J Clin Gastroenterol 1979; 1 (02) 131-143
• 105 Judson MA. Hepatic and splenic sarcoidosis. In: Baughman RP. , ed. Sarcoidosis: Lung Biology in Health and Disease. Vol 210. New York, NY: Marcel Dekker; 2006: 571-592
• 106 Vatti R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis: role of therapy in selected cases. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14 (01) 73-76
• 107 Israel HL, Margolis ML, Rose LJ. Hepatic granulomatosis and sarcoidosis. Further observations. Dig Dis Sci 1984; 29 (04) 353-356
• 108 Maddrey WC, Johns CJ, Boitnott JK, Iber FL. Sarcoidosis and chronic hepatic disease: a clinical and pathologic study of 20 patients. Medicine (Baltimore) 1970; 49 (05) 375-395
• 109 Kumar M, Herrera JL. Sarcoidosis and the liver. Clin Liver Dis 2019; 23 (02) 331-343
• 110 Sedki M, Fonseca N, Santiago P. , et al. Hepatic sarcoidosis: natural history and management implications. Front Med (Lausanne) 2019; 6: 232
• 111 Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager Jr H. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A case control etiologic study of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16 (01) 75-86
• 112 Judson MA, Costabel U, Drent M. , et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31 (01) 19-27
• 113 Warshauer DM, Molina PL, Hamman SM. , et al. Nodular sarcoidosis of the liver and spleen: analysis of 32 cases. Radiology 1995; 195 (03) 757-762
• 114 Kataria YP, Whitcomb ME. Splenomegaly in sarcoidosis. Arch Intern Med 1980; 140 (01) 35-37
• 115 Webb AK, Mitchell DN, Bradstreet CM, Salsbury AJ. Splenomegaly and splenectomy in sarcoidosis. J Clin Pathol 1979; 32 (10) 1050-1053
• 116 Bachmeyer C, Fayand A, Georgin-Lavialle S. , et al. Massive splenomegaly indicating sarcoidosis. Am J Med 2017; 130 (04) e141-e142
• 117 Mahévas M, Le Page L, Salle V. , et al. Thrombocytopenia in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (03) 229-235
• 118 Mahévas M, Chiche L, Uzunhan Y. , et al. Association of sarcoidosis and immune thrombocytopenia: presentation and outcome in a series of 20 patients. Medicine (Baltimore) 2011; 90 (04) 269-278
• 119 Ghaddar RK, Muzaffar TH. Pulmonary sarcoidosis and autoimmune hemolytic anemia: possible common immune pathogenesis. Arch Iran Med 2011; 14 (02) 146-148
• 120 Lower EE, Smith JT, Martelo OJ, Baughman RP. The anemia of sarcoidosis. Sarcoidosis 1988; 5 (01) 51-55
• 121 Yanardağ H, Pamuk GE, Karayel T, Demirci S. Bone marrow involvement in sarcoidosis: an analysis of 50 bone marrow samples. Haematologia (Budap) 2002; 32 (04) 419-425
• 122 Stone RW, McDaniel WR, Armstrong EM, Young Jr RC, Higginbotham-Ford EA. Acquired functional asplenia in sarcoidosis. J Natl Med Assoc 1985; 77 (11) 930-936 , 935–936
• 123 Warshauer DM, Dumbleton SA, Molina PL, Yankaskas BC, Parker LA, Woosley JT. Abdominal CT findings in sarcoidosis: radiologic and clinical correlation. Radiology 1994; 192 (01) 93-98
• 124 Folz SJ, Johnson CD, Swensen SJ. Abdominal manifestations of sarcoidosis in CT studies. J Comput Assist Tomogr 1995; 19 (04) 573-579
• 125 Britt AR, Francis IR, Glazer GM, Ellis JH. Sarcoidosis: abdominal manifestations at CT. Radiology 1991; 178 (01) 91-94
• 126 Scott GC, Berman JM, Higgins Jr JL. CT patterns of nodular hepatic and splenic sarcoidosis: a review of the literature. J Comput Assist Tomogr 1997; 21 (03) 369-372
• 127 Schupp JC, Freitag-Wolf S, Bargagli E. , et al. Phenotypes of organ involvement in sarcoidosis. Eur Respir J 2018; 51 (01) 1700991
• 128 Chopra A, Judson MA. How are cancer and connective tissue diseases related to sarcoidosis?. Curr Opin Pulm Med 2015; 21 (05) 517-524
• 129 Akmal M, Sharma OP. Renal sarcoidosis; a reminder. Chest 1990; 97 (06) 1284-1285
• 130 Hoitsma E, Faber CG, van Santen-Hoeufft M, De Vries J, Reulen JP, Drent M. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (01) 73-77
• 131 Dahan A, Dunne A, Swartjes M. , et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med 2013; 19: 334-345
• 132 de Kleijn WP, De Vries J, Lower EE, Elfferich MD, Baughman RP, Drent M. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med 2009; 15 (05) 499-506
• 133 De Vries J, Drent M. Relationship between perceived stress and sarcoidosis in a Dutch patient population. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21 (01) 57-63
• 134 De Vries J, Rothkrantz-Kos S, van Dieijen-Visser MP, Drent M. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21 (02) 127-136
• 135 De Vries J, Lower EE, Drent M. Quality of life in sarcoidosis: assessment and management. Semin Respir Crit Care Med 2010; 31 (04) 485-493
• 136 Ponhold W. The Löfgren syndrome: acute sarcoidosis (author's transl in German)]. Rontgenblatter 1977; 30 (06) 325-327
• 137 Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-related quality of life of persons with sarcoidosis. Chest 2004; 125 (03) 997-1004
• 138 Chang B, Steimel J, Moller DR. , et al. Depression in sarcoidosis. Am J Respir Crit Care Med 2001; 163 (02) 329-334
• 139 Yeager H, Rossman MD, Baughman RP. , et al; ACCESS Research Group. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 (02) 147-153
• 140 Hendriks C, Drent M, De Kleijn W, Elfferich M, Wijnen P, De Vries J. Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: a prospective follow-up study. Respir Med 2018; 138S: S24-S30